Across recent commercial launches, the gap between the 40% that beat forecast and the 60% that miss it comes down to a small set of decisions made early. Our 2026 analysis examined what the winners do differently — and why patient understanding sits at the center of it.
Industry analyses from McKinsey, Deloitte, EvaluatePharma, and IQVIA consistently put the drug launch failure rate at around 60%. Only 25% meet forecast. Just 15% exceed it.
Pharmaceutical companies spend between $475 and $830 million per launch on commercial activities — market access planning, field force training, medical education, patient support, and omnichannel engagement. With that level of capital deployed before any revenue is realized, an underperforming launch puts hundreds of millions at risk.
Clinical success does not guarantee commercial success. The question every launch leader is asking: what does the 40% that beats forecast do differently?
Only 15% of launches exceed forecast. Clinical data alone does not predict that outcome.
A continuously updated view of the patient journey — built from thousands of real patients, structured by AI, and refreshed as treatment, diagnosis, and patient expectations evolve. Launch teams plan against the patient reality that exists, not the one they assumed.
Across recent commercial launches, five drivers emerged consistently. Only one of them has anything to do with the drug itself.
Patient insight gaps account for 27% of launch failures — second only to market access.
Launch teams that miss forecast almost always describe the same problem in hindsight: the patient they planned for wasn't the patient who showed up. Diagnosis was harder than expected. Side effects were worse. Adherence was lower. The patient journey map informing the launch reflected a reality that had already moved on.
Launches that exceed forecast share a different pattern. Their commercial teams worked from a continuously updated view of the patient journey — built from real patient data rather than periodic research — and they planned against the patient reality that actually existed at launch.
The methodology shift sounds incremental. The operational shift across commercial, medical, and access functions is not.
Thousands of real patient conversations, structured by AI into a live view of symptoms, diagnosis delays, treatment hesitation, switching, side effects, and adherence. Every stage of the patient journey, KPI'd. Commercial, medical, and access teams plan against the same evidence — refreshed as the reality moves.
Three of the most-studied launch failures of the past decade. In every case, the clinical data was strong. The patient understanding wasn't.
Medicare restricted coverage. Doctors were unconvinced by mixed clinical data. High out-of-pocket costs and burdensome monitoring meant few patients could start therapy. Every root cause hit at once.
Severe diarrhea drove high discontinuation rates. Oncologists were unprepared to manage the side effect. The post-prescription journey was never mapped — and patients hit an adherence barrier the launch plan didn't address.
$14,000 annual price tag prompted strict prior authorization. Over 30% of patients prescribed discontinued therapy due to payer refusals. Access barriers killed uptake before patient experience could catch up.
Two real engagements with global pharma partners. Both started as a single-market pilot. Both scaled to a unified patient journey across multiple countries — built on real patient evidence, not internal assumption.
A top-10 global pharma pressure-tested its psoriasis patient journey against real-world data. Pilot in Germany, now live across five markets, feeding a digital companion's content pipeline directly.
A top-20 biopharma launched two first-in-category therapies into rare neuromuscular disease with no prior commercial playbook. Scaled to a pan-European patient journey at leadership level.
From single-market pilot to multi-country scale, every engagement follows the same shape. Pilot in one market. Validate the journey against real patient evidence. Scale across the portfolio. Built for launch teams under pressure to act.
Across the launches that meet or exceed forecast, three operational practices show up consistently. None require a different drug. All require a different relationship with patient evidence.
Don't wait until approval to address payer concerns. Engage payers in parallel with clinical development. Ground value narratives in patient-reported outcomes. Limited access drives 30% of failures — excelling here is the single largest performance lever.
Commercial, medical, access, and HEOR teams build strategy from the same continuously updated view of the patient. Conflicting narratives close. Trade-offs get easier. The patient journey becomes shared ground truth, not a deliverable owned by one team.
Map the patient journey continuously — symptom onset, diagnosis, access barriers, treatment initiation, side effects, adherence, switching. Lack of patient insight drives 27% of failures. The launches that win operate on what patients are actually experiencing, refreshed in near real time.
The launches beating forecast are the ones treating it that way — built on continuous patient evidence, refreshed in real time, planned against across every commercial function.
All statistics on this page are drawn from mama health's 2026 analysis, Commercial Drug Launches: Why 60% Fail. External research is sourced to McKinsey & Company, Deloitte, IQVIA, EvaluatePharma, Health Advances, Indegene, and case-specific industry reporting.